placebo + bevacizumab + platinum-based chemotherapy

This combination refers to a treatment regimen primarily used in clinical trials, particularly for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery. The regimen consists of: * **Placebo**: An inactive substance or treatment used as a control in clinical studies. * **Bevacizumab (Avastin)**: A monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF), inhibiting the growth of new blood vessels that tumors need to survive and grow. * **Platinum-based chemotherapy**: A class of cytotoxic drugs commonly used in cancer treatment, such as carboplatin or cisplatin, which work by damaging DNA and preventing cancer cells from dividing. This combination, often specifically bevacizumab plus platinum-based chemotherapy, is used in trials where the placebo arm serves as a control group receiving standard chemotherapy (plus placebo) to evaluate the added benefit of bevacizumab.